How often can Adalimumab be stopped during treatment?

Adalimumab is a fully human anti-TNF-α monoclonal antibody that is widely used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis and other chronic immune diseases. As a biological agent, adalimumab controls disease progression by continuously suppressing the inflammatory response. However, whether and when the drug can be "stopped once" or used intermittently must be determined based on the stability of the individual's condition, treatment goals and doctor's evaluation results, and cannot be interrupted at will.

After achieving remission, some patients hope to "try stopping" adalimumab to reduce drug burden or reduce the risk of long-term medication. However, research and clinical observations have found that most patients may relapse within weeks to months after stopping the drug, especially those with larger disease fluctuations or higher past activity. Therefore, it is generally recommended to continue taking the medication for at least 6 months and only after the doctor assesses that the condition is completely relieved (including clinical symptoms subsided and inflammatory indicators normalized), you can try to gradually extend the injection interval or stop the medication for a short period under close monitoring.

Some doctors adopt an "individualized reduction strategy" instead of discontinuing the drug directly, that is, after the patient stabilizes, they first change the frequency of medication from once every two weeks to once every three weeks, or even once every four weeks, to observe whether the effect can be maintained. This "intermittent management" can reduce the dosage of medication without making inflammation completely out of control. Once the patient's symptoms are found to have rebounded, such as worsening joint pain, recurrence of intestinal symptoms, or recurrence of skin lesions, the original dose can be restored in time to prevent rapid progression of the disease.

In addition, some special circumstances require short-term discontinuation of medication, such as preoperative preparation, occurrence of infection (such as pneumonia, resurgence of tuberculosis), vaccination, etc. In these cases, doctors may recommend suspending 1 to 2 injections (i.e. 2 to 4 weeks) and resuming the medication when the risk has resolved. Such discontinuation requires careful evaluation in patients at low risk for relapse and usually does not have serious consequences.

In summary, adalimumab is not a drug suitable for "regular discontinuation once", and its treatment principle emphasizes "continuous control". Any decision to discontinue medication must be made under the guidance of a physician and based on the degree of disease remission. Blind interruption may lead to recurrence or even worsening, affecting long-term prognosis. If the patient wishes to discontinue the medication, it is recommended to communicate with the doctor in advance and develop an individualized monitoring and dose reduction plan to ensure safety and continuity of treatment.

Reference materials:https://www.drugs.com/